- Home
- CVKD vs PULM Comparison
CVKD vs PULM Comparison
Compare CVKD & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- PULM
- Stock Information
- Founded
- CVKD 2022
- PULM 2003
- Country
- CVKD United States
- PULM United States
- Employees
- CVKD N/A
- PULM N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- PULM Health Care
- Exchange
- CVKD Nasdaq
- PULM Nasdaq
- Market Cap
- CVKD 29.5M
- PULM 33.2M
- IPO Year
- CVKD 2023
- PULM N/A
- Fundamental
- Price
- CVKD $12.32
- PULM $7.43
- Analyst Decision
- CVKD Strong Buy
- PULM
- Analyst Count
- CVKD 1
- PULM 0
- Target Price
- CVKD $32.00
- PULM N/A
- AVG Volume (30 Days)
- CVKD 20.0K
- PULM 34.5K
- Earning Date
- CVKD 08-06-2025
- PULM 08-12-2025
- Dividend Yield
- CVKD N/A
- PULM N/A
- EPS Growth
- CVKD N/A
- PULM N/A
- EPS
- CVKD N/A
- PULM N/A
- Revenue
- CVKD N/A
- PULM $1,921,000.00
- Revenue This Year
- CVKD N/A
- PULM N/A
- Revenue Next Year
- CVKD N/A
- PULM $134.88
- P/E Ratio
- CVKD N/A
- PULM N/A
- Revenue Growth
- CVKD N/A
- PULM N/A
- 52 Week Low
- CVKD $5.70
- PULM $1.78
- 52 Week High
- CVKD $22.90
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- CVKD 38.54
- PULM 49.28
- Support Level
- CVKD $13.12
- PULM $8.49
- Resistance Level
- CVKD $15.99
- PULM $8.75
- Average True Range (ATR)
- CVKD 0.76
- PULM 0.42
- MACD
- CVKD -0.08
- PULM -0.14
- Stochastic Oscillator
- CVKD 6.45
- PULM 0.11
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).